V600K-Mutant Melanoma May Merit First-Line Immunotherapy

(MedPage Today) -- Higher mutational load is less responsive to targeted therapy with BRAF/MEK inhibition
Source: MedPage Today Dermatology - Category: Dermatology Source Type: news